Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade iii for a period 2003-2011

Abstract

In this small descriptive study, conversion from CNI to SRL was followed by an increased incidence of infections and consecutive 25-50% dose reduction in the second antiproliferative agent (AZA, MMF), with a possible influence on the development of glomerulopathy in some patients, which was the major reason for discontinuation of SRL therapy in the 7 (29%) patients. Nine (37.5%) of the patients experienced the greatest benefit of CIN to SRL conversion without serious post-conversion complications.

mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis

“…Thus, nine publications remained to be fully read. [8][9][10][11][12][13][14][15][16] One paper was excluded because it was duplicate 11 and another because the number of cases of ovarian cysts was not reported, although they were described as 'very frequent'. 16 One paper 13 reported the update of a previous one; 12 thus, the latter 12 was excluded from the main analysis but included in the subanalysis for menopausal status, since this information was missing in the updated report.…”

“…9 Alfadhli et al's study was of some concern because it was unclear if baseline ultrasound scans were detailed enough to identify ovarian cysts. 8 Del Olmo Garcia et al 13 and Ignjatović et al 15 presented mainly descriptive articles, including 18 (13 of whom already included in the paper by Cure et al 12 ) and 6 women, respectively. Therefore, the possibility of some NOS quality item evaluation was debatable (ie, if sample size was too little to control for important factors or if a not exposed cohort did exist).…”

“…One patient presented with acute abdominal pain and a large cyst of the left ovary while receiving SRL and underwent surgery. Ignjatović et al 15 reviewed 24 transplant patients (6 women) who switched from calcineurin inhibitors (CNI) to SRL from 2003 to 2011. Patients converted from CNI to SRL, with target serum levels 7-10 ng/mL for months 6-12 after transplant, and 5-10 ng/mL thereafter.…”